Recombinant CD19 (Inebilizumab Biosimilar) antibody
Reactivity: Human
ELISA, FACS, SPR, Func, BLI
Host: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all CD19 (Inebilizumab Biosimilar) products
- CD19 (Inebilizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Human
- Expression System
- CHO Cells
-
Clonality
- Monoclonal
-
Conjugate
- This CD19 (Inebilizumab Biosimilar) antibody is un-conjugated
- Application
- ELISA, Flow Cytometry (FACS), Surface Plasmon Resonance (SPR), Functional Studies (Func), Bio-Layer Interferometry (BLI)
- Purpose
- Anti-CD19 Reference Antibody (inebilizumab)
- Characteristics
- Anti-CD19 Reference Antibody (inebilizumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 147.42 kDa.
- Purity
- >95 %
- Isotype
- IgG1
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Comment
-
Conditions: B-cell malignancies Chronic Lymphocytic Leukemia Multiple Myeloma Neuromyelitis optica spectrum disorder Scleroderma
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Concentration
- 1 mg/mL
- Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- Storage
- 4 °C,-80 °C
- Storage Comment
- +4°C,-80°C
-
- Target
- CD19 (Inebilizumab Biosimilar)
- Abstract
- CD19 (Inebilizumab Biosimilar) Products
- Target Type
- Biosimilar
- Molecular Weight
- 147.42 kDa
- UniProt
- P15391
-
You are here:
